New biosimilar aims to match keytruda in melanoma fight
NCT ID NCT06551064
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This study compares FYB206, a biosimilar (a very similar copy) of the cancer drug Keytruda, to the original Keytruda in 96 adults with stage IIB/IIC or III melanoma that has been completely removed by surgery. The goal is to see if FYB206 stays in the body the same way as Keytruda, which helps the immune system attack cancer cells and prevent the cancer from coming back. Participants will receive either FYB206 or Keytruda after surgery, and researchers will measure drug levels and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Formycon Investigative Site
Sarajevo, Bosnia and Herzegovina
-
Formycon Investigative Site
Sofia, Bulgaria
-
Formycon Investigative Site
Tartu, Estonia
-
Formycon Investigative Site
Batumi, Georgia
-
Formycon Investigative Site
Kutaisi, Georgia
-
Formycon Investigative Site
Tbilisi, Georgia
-
Formycon Investigative Site
Kaunas, Lithuania
-
Formycon Investigative Site
Chisinau, Moldova
-
Formycon Investigative Site
Skopje, North Macedonia
-
Formycon Investigative Site
Krakow, Poland
-
Formycon Investigative Site
Lodz, Poland
-
Formycon Investigative Site
Bucharest, Romania
-
Formycon Investigative Site
Cluj-Napoca, Romania
-
Formycon Investigative Site
Belgrade, Serbia
-
Formycon Investigative Site
Kragujevac, Serbia
-
Formycon Investigative Site
Niš, Serbia
-
Formycon Investigative Site
Kyiv, Ukraine
Conditions
Explore the condition pages connected to this study.